BACKGROUND: The ImmuKnow (Cylex Inc, Columbia, MD) assay measures the amount of adenosine triphosphate (ATP) produced by helper CD4(+) cells after stimulation with a T-cell mitogen. We hypothesized that this assay can be used to assess the immune function of lung transplant recipients and identify those at risk of developing acute cellular rejection and respiratory infection. METHODS: Lung transplant recipients at University of California Los Angeles between January 1, 2006 and December 31, 2009 received a bronchoscopy with broncheoalveolar lavage, transbronchial biopsy and ImmuKnow values drawn at regular intervals as well as during episodes of clinical deterioration. The recipient's clinical condition at each time-point was classified as healthy, acute cellular rejection, or respiratory infection. Mixed-effects models were used to compare the ATP levels among these groups, and odds ratios for rejection and infection were calculated. RESULTS: The mean ATP level was 431 ± 189 ng/ml for the rejection group vs 377 ± 187 ng/ml for the healthy group (p = 0.10). A recipient with an ATP level > 525 ng/ml was 2.1 times more likely to have acute cellular rejection (95% confidence interval [CI] 1.1-3.8). Similarly, the mean ATP level was 323 ± 169 ng/ml for the infection group vs 377 ± 187 ng/ml for the healthy group (p = 0.03). A recipient with an ATP level < 225 ng/ml was 1.9 times more likely to have respiratory infection (95% CI, 1.1-3.3). However, the test was associated with poor performance characteristics. It had low sensitivity, specificity with an area under the receiver operating characteristic curve of only 0.61 to diagnose rejection and 0.59 to diagnose infection. CONCLUSIONS: The ImmuKnow assay appears to have some ability to assess the overall immune function of lung transplant recipients. However, this study does not support its use as a reliable predictor of episodes of acute cellular rejection or respiratory infection.
BACKGROUND: The ImmuKnow (Cylex Inc, Columbia, MD) assay measures the amount of adenosine triphosphate (ATP) produced by helper CD4(+) cells after stimulation with a T-cell mitogen. We hypothesized that this assay can be used to assess the immune function of lung transplant recipients and identify those at risk of developing acute cellular rejection and respiratory infection. METHODS: Lung transplant recipients at University of California Los Angeles between January 1, 2006 and December 31, 2009 received a bronchoscopy with broncheoalveolar lavage, transbronchial biopsy and ImmuKnow values drawn at regular intervals as well as during episodes of clinical deterioration. The recipient's clinical condition at each time-point was classified as healthy, acute cellular rejection, or respiratory infection. Mixed-effects models were used to compare the ATP levels among these groups, and odds ratios for rejection and infection were calculated. RESULTS: The mean ATP level was 431 ± 189 ng/ml for the rejection group vs 377 ± 187 ng/ml for the healthy group (p = 0.10). A recipient with an ATP level > 525 ng/ml was 2.1 times more likely to have acute cellular rejection (95% confidence interval [CI] 1.1-3.8). Similarly, the mean ATP level was 323 ± 169 ng/ml for the infection group vs 377 ± 187 ng/ml for the healthy group (p = 0.03). A recipient with an ATP level < 225 ng/ml was 1.9 times more likely to have respiratory infection (95% CI, 1.1-3.3). However, the test was associated with poor performance characteristics. It had low sensitivity, specificity with an area under the receiver operating characteristic curve of only 0.61 to diagnose rejection and 0.59 to diagnose infection. CONCLUSIONS: The ImmuKnow assay appears to have some ability to assess the overall immune function of lung transplant recipients. However, this study does not support its use as a reliable predictor of episodes of acute cellular rejection or respiratory infection.
Authors: S A Yousem; G J Berry; P T Cagle; D Chamberlain; A N Husain; R H Hruban; A Marchevsky; N P Ohori; J Ritter; S Stewart; H D Tazelaar Journal: J Heart Lung Transplant Date: 1996-01 Impact factor: 10.247
Authors: Elfriede Ruttmann; Christian Geltner; Brigitte Bucher; Hanno Ulmer; Daniel Höfer; Herbert B Hangler; Severin Semsroth; Raimund Margreiter; Günther Laufer; Ludwig C Müller Journal: Transplantation Date: 2006-05-27 Impact factor: 4.939
Authors: Richard J Kowalski; Diane R Post; Roslyn B Mannon; Anthony Sebastian; Harlan I Wright; Gary Sigle; James Burdick; Kareem Abu Elmagd; Adriana Zeevi; Mayra Lopez-Cepero; John A Daller; H Albin Gritsch; Elaine F Reed; Johann Jonsson; Douglas Hawkins; Judith A Britz Journal: Transplantation Date: 2006-09-15 Impact factor: 4.939
Authors: S S Weigt; A Derhovanessian; E Liao; S Hu; A L Gregson; B M Kubak; R Saggar; R Saggar; V Plachevskiy; M C Fishbein; J P Lynch; A Ardehali; D J Ross; H-J Wang; R M Elashoff; J A Belperio Journal: Am J Transplant Date: 2011-12-07 Impact factor: 8.086
Authors: Peter M Hopkins; Christina L Aboyoun; Prashant N Chhajed; Monique A Malouf; Marshall L Plit; Stephen P Rainer; Allan R Glanville Journal: Am J Respir Crit Care Med Date: 2004-08-05 Impact factor: 21.405
Authors: Anthony P Khalifah; Ramsey R Hachem; Murali M Chakinala; Kenneth B Schechtman; G Alexander Patterson; Daniel P Schuster; Thalachallour Mohanakumar; Elbert P Trulock; Michael J Walter Journal: Am J Respir Crit Care Med Date: 2004-05-06 Impact factor: 21.405
Authors: Vijaiganesh Nagarajan; Adrian V Hernandez; Clay A Cauthen; Randall C Starling; W H Wilson Tang Journal: Am Heart J Date: 2016-09-30 Impact factor: 4.749
Authors: John R Greenland; Tiffany Chong; Angelia S Wang; Emily Martinez; Pavan Shrestha; Jasleen Kukreja; Steven R Hays; Jeffrey A Golden; Jonathan P Singer; Qizhi Tang Journal: Am J Transplant Date: 2018-05-22 Impact factor: 8.086